However, other studies conducted in vivo, with data and samples from HER2+ breast cancer and gastrointestinal patients, indicate that tumors expressing the d16HER2 isoform are sensitive to trastuzumab [106,107,108,109]. This evidence concerns the gene ERBB2 and breast cancer.